Clinical Trials

24 enrolled

Neurofibromatosis 1

NCT02143466 2026-01-30

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

344 enrolled

Advanced Non Small Cell Lung Cancer

NCT04590235 2026-01-30

A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)

32 enrolled

Phase 3 Active not recruiting

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT04924608 2026-01-12

KOMET

145 enrolled 17 charts 1 FDA

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT02546661 2025-12-29

BISCAY

Phase 1/2 Active not recruiting

117 enrolled

Genitourinary

Muscle Invasive Bladder Cancer

NCT05309668 2025-12-18

SPRINKLE

36 enrolled 37 charts

Neurofibromatosis 1

NCT00463814 2025-11-13

AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies

58 enrolled

Neoplasms

NCT00600496 2025-11-13

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

BreastDermatologicGastrointestinalGenitourinaryThoracic

140 enrolled

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

NCT03944772 2025-01-30

ORCHARD

Phase 2 Active not recruiting

247 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03833427 2024-11-07

MK-5618-001

Phase 1 Terminated

32 enrolled 17 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT05825365 2023-08-14

PROTECT

Phase 2 Withdrawn

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT03745989 2023-07-27

MK-8353-014

30 enrolled 19 charts

Neoplasm Metastasis

NCT00085787 2020-10-14

A Study of ARRY-142886 in Patients With Advanced Cancer

57 enrolled

Advanced Cancer

NCT03259633 2020-05-01

An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1

Approved for marketing

Neurofibroma, Plexiform

NCT02586987 2019-11-18

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

BreastDermatologicGastrointestinalThoracic

58 enrolled

Biliary Tract Neoplasms, Breast Neoplasms, Lung Neoplasms, Melanoma, Colorectal Neoplasms, Disease Progression

NCT01843062 2019-08-28

ASTRA

Phase 3 Terminated

233 enrolled 14 charts

EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT01021748 2018-08-07

A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)

63 enrolled 17 charts

Locally Advanced or Metastatic Solid Tumors

NCT00890825 2018-06-20

AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients

88 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung

NCT01605916 2016-10-21

Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer

33 enrolled 24 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Neoplasms

NCT02322749 2016-08-31

A Study to Assess the Relative Bioavailability of Process Variants of Selumetinib in Healthy Male Volunteers

48 enrolled 16 charts

Neoplasms

NCT02063230 2016-07-21

To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects

32 enrolled 12 charts

Solid Tumors

NCT01949870 2016-05-13

Selumetinib (AZD6244, ARRY-142886) J-BTC Phase 1 Study

Phase 1 Terminated

6 enrolled 6 charts

Gastrointestinal

Biliary Tract Neoplasms

NCT02238782 2016-04-05

A Study to Assess the Absolute Bioavailability of Oral Selumetinib in Healthy Male Volunteers.

21 enrolled 4 charts

Neoplasms

NCT00936221 2016-03-14

Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients

385 enrolled 11 charts

Dermatologic

Melanoma

NCT02056392 2015-11-09

To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers

54 enrolled 31 charts

Solid Tumours

NCT01931761 2015-06-30

Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] Selumetinib in Volunteers

6 enrolled

Solid Tumours

NCT02063204 2015-06-30

To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects

24 enrolled

Renal Insufficiency

NCT02093728 2015-06-30

To Assess the Effect of Itraconazole and Fluconazole on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers

26 enrolled

Solid Tumours

NCT00338130 2014-08-13

Randomised Study to Compare the Efficacy of AZD6244 vs TMZ

239 enrolled

Dermatologic

Melanoma

NCT00372788 2014-08-13

AZD6244 Versus Pemetrexed (Alimta®) in Patients With Non-small Cell Lung Cancer, Who Have Failed One or Two Prior Chemotherapy Regimen

88 enrolled

Carcinoma, Non-Small-Cell Lung

NCT00372944 2014-08-13

AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy

70 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT00514761 2014-08-13

Phase II Efficacy Study of AZD6244 in Colorectal Cancer

64 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT00710515 2014-08-13

Study to Assess the Effect of Dosing AZD6244 HydSulfate in the Presence and Absence of Food in Patients With Advanced Solid Malignancies

30 enrolled

Dermatologic

Melanoma

NCT01974349 2014-08-13

To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers

39 enrolled

Solid Tumours

NCT01960374 2014-06-02

Dose-escalation Study to Assess Selumetinib Safety, Tolerability and PK

117 enrolled

Healthy Volunteers Pharmacokinetic Study

NCT02046850 2014-04-29

To Assess the Effect of Rifampicin on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers

24 enrolled